Company intelligence / Profile preview
Fu Shan
Hangzhou, Zhejiang, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Fushan Pharmaceutical is a China-based biopharmaceutical company focused on the development of innovative therapies for metabolic and endocrine disorders. The company specializes in the research and commercialization of treatments for type 2 diabetes, obesity, and related metabolic conditions. Its pipeline features several candidates targeting the GLP-1 pathway, including both small molecule and biologic approaches. Fushan Pharmaceutical aims to address significant unmet medical needs in the metabolic disease space through advanced drug delivery and novel mechanism-of-action strategies. The company maintains a strong presence in the domestic Chinese market while exploring global development opportunities.
- Therapeutic areas
- EndocrinologyGastroenterology
- Modalities
- Small moleculeBiologicRecombinant protein
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Fu Shan.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fu Shan.